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Breast cancer comprises approximately
13 .9% of all cases of malignancy in both sexes
and 19% in women, in whom it is the commonest form of cancer . 1 The American Cancer Society estimates that 11 0,000 women developed
breast cancer in 1 981 , and some 3 7 , 1 00
deaths from the disease occurred. ~ The fiveyear survival rate has been improving over the
past 40 years as shown in Table 1 1 , but patients remain in risk of recurrence indefinitely,
and survival for ten years is generally accepted
as the minimal time period necessary to establish the validity of new therapies.
Data from the first study of the National
Surgical Adjuvant Breast and Bowel Project
(NSABP) are shown in Table 2 and indicate that
the majority of women with breast cancer ultimately succump to the di$ease.3 Thus, although
only 1 0% of cases present with metastatic disease (an additional 5% predictably have very
rapid progression : inflammatory carcinoma, extensive local or regional disease), over half of
those undergoing mastectomy will develop recurrence within ten years .
The identification of women with either adverse or favorable prognostic features modifies
these figures considerably. Among the important favorable variables are : attainment of
menopausal status for at least five years ; in-

creasing age; primary tumors two cm in diameter or less; absence of regional node involvement ; estrogen and progesterone receptor
positivity and , for estrogen receptors at least ,
absolute amount of receptor; delay between initial presentation and recurrence ; skin or nodal
local recurrence as opposed to visceral metastasis; and perhaps most important, an overall
less aggressive biological character of the tumor.
Adverse prognostic features include : a
clinical picture of inflammatory carcinoma; concurrent pregnancy ; liver metastasis; multiple visceral metastases at presentation ; brain, meningeal, epidural involvement, or spinal cord
compression secondary to vertebral collapse ;
lymphangitic pulmonary spread; absence of estrogen and, possibly , progesterone receptor;
failure of previous therapy for systemic disease;
and inability to withstand the toxicities associated with chemotherapy or hormonal therapy .
An excellent review of all phases of breast cancer has recently been published .5
I intend to concentrate on four areas in
greater detail : 1) the usefulness of receptor assays in predicting the response to therapy ; 2)
chemotherapy of advanced metastatic disease;
3) adjuvant chemotherapy following surgery; 4)
the usefulness of antiestrogens in hormonallyresponsive disease.
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Receptor Assays
Steroid hormones are known to act by
crossing the cell membrane where they bind to
specific cytoplasmic receptors . The receptorsteroid complex is activated and translocates to
the nucleus where it interacts with chromatin.
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TABLE 1
Five-Year Survival Rates In Breast Cancer
1940-1949
1953-1959
1960-1964
1965-1969

TABLE 3
Objective Response to Endocrine Therapy
No. Responding /
No.
Evaluable

53%
60%
62%
64%

(Note: Adapted from Cutler SJ, Myers, MH, Green SB:
Trends in survival rates of patients with cancer. N Engl J
Med 293: 122-124, 1975.)
(By Permission)

As a result of this interaction , RNA synthesis is
increased and new proteins are synthesized.6 It
now seems that the appearance of progesterone receptors in breast tumors is the result of
estrogen stimulation and is a measure of hormonal responsiveness (Table 3).7
The presence of estrogen receptor (ER) is
an important determinant of prognosis independent of the effects of age, nodal involvement and primary lesion size (Table 4).
The ER level is less in the tumors of younger
women and is less in primary as opposed to
metastatic tumor (Table 5).7
Estrogen receptor positivity successfully
predicts objective responses to hormonal therapy (Table 6) to the extent that only ER+ patients should be treated initially with ablation or
hormone administration. 7 ·8 It is of interest that
the perimenopausal patient, classically not responsive to hormonal therapy , tends to have
lower ER positivity than either the premenopausal or postmenopausal (five years or more)
patient. Clearly the traditional treatment decision based on premenopausal or postmenopausal status alone must be modified to
include ER status.

Estrogen-Receptor Negative/
Progesterone-Receptor
Negative
Estrogen-Receptor Positive/
Progesterone-Receptor
Positive

Ten-Year
Treatment
Failure Rate
Negative nodes
Positive nodes:
1- 3
4 or more
All
All patients

Ten-Year
Survival

24%

65%

65%
86%
76%
50%

38%
13%
25%
46%

(Note: Adapted from the first NSABP Protocol)
(By Permission)

9/ 63

14%

67 / 91

74%

(Note: Adapted from McGuire WL: Hormone receptors:
Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433 , 1978)
(By Permission)

Chemotherapy of Advanced Breast Cancer
A large number of chemotherapeutic
drugs have been shown to produce objective
responses defined as partial and complete responses (Table 7). Table 8 lists a number of the
commonly used agents and responses. The
early studies of Greenspan and others suggested that combination therapy was considerably more effective, and therefore the initial
chemotherapeutic treatment is almost always a
combination, most commonly Cytoxan-Methotrexate-5-fluorouracil (CMF). The CMF combination shown in Table 9 is based on an Eastern
Cooperative Oncology Group (ECOG) protocol
with 49 /93 patients responding . Complete responses lasted a median of eight or more
months, partial responses four to eight months.
Many oncologists, including myself, use less
Methotrexate, 30-40 mgm/M 2 , and one series
TABLE 4
Estrogen Receptor and the Prognosis for Early
Recurrence of Breast Cancer

Category

TABLE 2
Results of Surgical Treatment Alone

%
Response

Age:
Less than 50
Over 50
Nodes involved:

0
1-3
4 or more
Size of primary:
Less than 2 cm
Greater than 2 cm

Recurrence at 18 months(%)
EstrogenEstrogenReceptor
Receptor
Negative
Positive

34
35

14
8

12
38
62

6 .5
12.5
27.0

33
31

0
14

(Note: Adapted from Table 1, McGuire WL: Semin Oncol 5:
428, 1978, and Knight WA, et al: Cancer Res 37 : 4669,
19 77 .) (By Permlaslon)
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TABLE 5
Distribution of Estrogen Receptor in Primary and Metastatic Breast Cancer

Age:
ER level :
Under 3
3-10
11-1 00
101-2000

Primary Biopsy
Under50
50 or over
37%
20%
41%
2%

Metastatic Biopsy
Under 50
50 or over

23%
15%
36%
20%

52%
14%
29%
5%

31%
16%
27%
20%

(Note: Taken from Table 2, McGuire WL: Semin Oneal 5: 429, 1978.) (By Permission)

showed a 62% respon$e rate with CMF using
Methotrexate at 40 mgm/M 2 .
There is no doubt that the single most effective drug is doxorubicin hydrochloride (Adriamycin(R)) with reported response rates of up to
45%. Combinations using Adriamycin also show
a higher response rate than CMF or CMFP
(See Table 9), and some oncologists use CAF
as the initial treatment. It is, however, desirable to
have a combination available for use after the
initial treatment fails, and we have tended to
reserve Adriamycin for wse in relapse, usually
combining it with the vinca alkaloid, vincristine. 4
An exception to this sequence is the premenopausal, ER- patient with extensive visceral and bone disease. These women usually
have very rapid, progressive disease, and initial
treatment with CAF is warranted in an attempt
to obtain even a small measure of control of
their disease .
An additional consideration is the treat-

ment of the ER+ patient with, combined hormonal and chemical therapy. Only some 1020% of objective responses are complete responses, but patients achieving complete responses tend to have longer remissions and
better survival. Moreover, a small number may
be curable since the achievement of complete
response in large numbers of patients has been
associated historically with the development of
very long-term survival or cure. Thus attempts
to increase the number of patients achieving
complete response and to maintain those in
complete response for as long as possible are
now the subject of intense study.
Legha and his colleagues at the M. D. Anderson Hospital and Tumor Institute recently reported on 11 6 patients with breast cancer
achieving complete remission . A marked improvement in the number in complete response
and the duration of complete response was
seen in premenopausal patients who underwent

TABLE 6
Objective Response by Therapy and Estrogen .Receptor
Therapy

Ablative Surgery:
Adrenalectomy
Oophorectomy
Hypophysectomy
Total
Hormonal Therapy:
Androgens
Estrogens
Glucocorticoid
Total
Antiestrogens:
Nafoxidine
Tamoxifen
Total

ER+
#%

Objective Response / Evaluable Patients
ER #%

40 / 76 (53%)
28/43 (65%)
9/14 (64%)
77 / 133(58%)

4 / 41 (10%)
2/74 ( 3%)
0/12 ( 0%)
6/ 127( 5%)

28%
29%
33%

10/28 (36%)
38 / 60 (63%)
15 / 32 (47%)
63 / 1 20(53%)

2/22
2/ 49
0/ 19
4 / 90

18%
36%
29%

12 / 17 (71%)
18 / 40 (45%)
30 / 57 (53%)

0/ 16 ( 0%)
0/ 15 ( 0%)
0/ 31 ( 0%)

(
(
(
(

9%)
4%)
0%)
4%)

Pre-ER patients
(All comers)

33%

(Note : Adapted from Table 2, Legha SS et al : Ann Intern Med 88: 69, 1978, and Table 4 , Carbone PP , Davis TE: Semin Oneal
5: 417, 1978.) (By Permission)
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TABLE 7
Tumor Response
Complete Remission

Complete Response
Partial Response

Stable Disease

Progressive Disease

No clinical evidence of active
tumor; no subjective evidence
of disease
All measurable disease disappears
50% or greater reduction in measurable tumor in the absence of
progression or recurrence of
new lesions elsewhere
Steady state or response less than
50% reduction in measurable
tumor. No increase in size of
any lesion or appearance of
new lesions
Occurrence of any new lesion or
increase of any measurable
lesion> 50%, even in the face
of regressing lesions
elsewhere

(Note. Adapted from Carter SK: The design of clinical trials

in cancer therapy (ed M Staquet) Brussels: Editions Scientifiques Europeennes, 1972.) (By Permission)

oophorectomy and received chemotherapy immediately compared to women receiving chemotherapy when disease progression occurred. 9
An earlier study of adrenalectomy, oophorectomy and chemotherapy by Hoge et al revealed a much higher objective response rate
(80%) when compared to chemotherapy or hormonal ablation alone. 10 These and other studies
suggest that attempts to increase the number of
patients in complete response by combined
therapy may be worthwhile. However , such
studies remain research protocols, and much
longer observation will be necessary to assess
their true value.

Adjuvant Chemotherapy
The large number of patients failing to
achieve cure following radical mastectomy sug-

TABLE 8
Summary of Single Agents Active Against Advanced Breast Cancer

Drug
Alkylating agents:
Cyclophosphamide
Nitrogen mustard
Phenylalanine mustard
Chlorambucil
Thio-TEPA
Antimetabolites:
5-Fluorouracil
Methotrexate
6-Mercaptopurine
Arabinosyl cytosine
Vinca Alkaloids:
Vincristine
Vinblastine
Antibiotics:
Actinomycin D
Adriamycin
Bleomycin
Mithramycin
Mitomycin
Miscellaneous agents:
Hydroxyurea
BCNU
CCNU
Methyl CCNU
Hexamethylmelamine
lmidazole carboxamide
Procarbazine

No. Evaluable
Patients

No. Objective
Responses

Response
(%)

529
92
86
54
162

182
32
20
11
48

34
35
23
20
30

1263
356
45
64

324
120
6
6

26
34
13
9

226
95

47
19

21
20

44
193
8
32
60

5
67
0
5
23

11
35
0
16
38

21
76
155
33
39
29
21

4
16
18
2
11
2

19
21
12
6
28
7
5

(Note: Compiled by Susan J. Mellette, MD , Professor of Medicine, Medical College of Virginia .)
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TABLE 9
Useful Drug Combinations In the Treatment of Breast Cancer
Regimen
CMFVP

CMF

CMFP

AV

CA

CAF

DAV

Drug Dosage

Response Rate(%)

and Schedule

Cyclophosphamide 80 mg / m 2 p.o. daily
Methotrexate
20 mg / m 2 i.v . weekly
Fluorouracil
500 mg / m 2 i.v. weekly
Vincristine
1 .0 mg / m 2 p.o. daily x 15
Cyclophosphamide 100 mg / m 2 p.o. days 1- 14
60 mg / m 2 i. v. days 1 & 8
Methotrexate
5-Fluorouracil
600 mg / m 2 i.v. days 1 & 8
(repeat cycles every 4 weeks)
Cyclophosphamide 1 00 mg / m 2 p.o . days 1-14
Methotrexate
60 mg / m 2 i. v. days 1 & 8
5-Fluorouracil
600 mg / m 2 i.v. days 1 & 8
Prednisone
40 mg / m 2 p.o. days 1-14
(repeat cycles every 4 weeks)
Adriamycin
75 mg / m 2 i.v. day 1
Vincristine
1 .4 mg / m 2 i.v. day 1 & 8
(repeat cycles every 3 weeks)
Cyclophosphamide 200 mg / m 2 p.o. days 3-6
Adriamycin
40 mg / m 2 i.v. day 1
(repeat cycles every 3-4 weeks)
Cyclophosphamide 100 mg / m 2 p.o . days 1-14
Adriamycin
30 mg / m 2 i.v . days 1 & 8
500 mg / m 2 i.v. days 1 & 8
Fluorouracil
(repeat cycles every 4 weeks)
Dibromodulcitol
150 mg / m 2 p.o . days 1-10
Adriamycin
45 mg / m 2 i.v . day 1
Vincristine
1 .2 mg / m 2 i.v . day 1
(repeat cycles every 4 weeks)

(Note: From Table 3 . Carbone PP , Davis TE : Semin Onco/ 5 :417 , 1978.)

gests that breast cancer is in fact a systemic
disease at a very early stage , if not at its onset .
There is increasing evidence to support a multicentric origin for many tumors including breast
cancer, and it is now apparent that very large
numbers of cells are shed systemically by even
small cancers . Moreover, surgical failure results
in local recurrence in only about 15% of cases,
and most of these patients eventually show dissemination at other sites. 4 Adjuvant chemotherapy given after surgery is designed to destroy
disseminated tumor cells and increase the likelihood of cure.
Two major groups have studies in progress: the National Surgical Adjuvant Breast Project (NSABP) and the National Tumor Institute in
Milan. 11 · 1 2 • 13 The initial NSABP trial used a
single drug , L-phenylalanine mustard, and the
first Milan study used CMF for 12 cycles . Benefit was seen in premenopausal patients with one
to three nodes involved in both series and for
four or more nodes in the Milan series. Tables
1 OA and 1 OB show data updated to four years
102 /
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62

(then taper) !
53

63

52

74

82

71

(By Permission)

as of May 1 9 7 8 and represent the most recent
comparative data. No benefit to premenopausal
women without nodal involvement has been
demonstrated . The situation for postmenopausal women is less certain at present
because the Milan study is reported to show
benefit for the woman with four or more nodes
who is able to take 85% or more of the scheduled adjuvant chemotherapy. 13 The NSABP
data do not show benefit. Therefore adjuvant
therapy should be reserved for premenopausal
women with one or more positive axillary nodes.
To date, a clear-cut advantage for three drugs
and for the duration of treatment has not been
established, although treatment for six months
and 1 2 months does not appear much different
at the present. 1 4
Antiestrogens
A number of steroidal and non-steroidal
compounds have antiestrogenic effects. Most
clinical trials have employed the nonsteroidal
compounds nafoxidine and tamoxifen . The lat-

TABLE 10
A. Comparison of NSABP /Milan Data
-Control Patients-

B. Comparison of NSABP /Miian Data
-Treated Patients-

% Disease Free

% Disease Free

at Four Years

at Four Years
Age /
Menopause
All Pts.
All Pts.
All Pts.
49 / Pre50/ Post49 / Pre49 / Pre50 / Post50 / Post-

Positive
Nodes

NSABP

Milan

All
1-3
4
All
All
1-3
4
1-3
4

51
63
40
43
56
54
35
67
43

47
54
32
41
52
49
23
58
42

Age/
Menopause
All Pts.
All Pts.
All Pts.
49 / Pre50 / Post49 / Pre49 / Pre50 / Post50 / Post-

Positive
Nodes

NSABP

Milan

All
1-3
4
All
All
1-3
4
1- 3
4

59
74
40
65
56
86
40
68
40

66
74
49
75
56
87
51
61
1 45
5 / 78

5/ 78

-

(Note: Courtesy of Dr. Bernard Fisher and the National Surgical Adjuvant Breast Project.)

ter is commercially available and is believed to
bind to the estrogen receptor in the cytosol ,
translocate to the nucleus, and bind to chromatin but not release easily. Cytoplasmic receptors
also are depleted after tamoxifen therapy. It is
clear that the effectiveness of antiestrogenic
treatment correlates very well with estrogen-receptor positivity. An overall response rate of
about 33% is seen, but the rate in ER+, postmenopausal patients is as high as 60%. 15 This
is similar to the percentage of tamoxifen response in patients previously responding to hormonal therapy. Patients failing to respond to
hormonal therapy usually do not respond to tamoxifen.
Most studies have been done in postmenopausal patients, but benefit in premenopausal patients has not been excluded .
The dose is 1 0 mgm by mouth twice a day and
is usually tolerated well . Nausea and vomiting
are seen in some patients (12% in one series) ,
hot flushes in about 21 %, hypercalcemia occasionally , and mild platelet count depression
rarely.
Synthesis
The management of the patient with
breast cancer increasingly depends on careful
staging taking into account the major prognostic features outlined above. The patient _with localized disease, small primary and no axillary
nodes is probably best served at present by
modified radical mastectomy or radical mastectomy, although studies in progress at a large
number of centers are beginning to suggest that

less extensive surgery with radiation therapy to
the chest wall and nodes may be useful in selected cases. Knowledge of the presence or absence of axillary node metastasis and the number of nodes involved is of such central
importance to prognosis that procedures which
do not provide this information cannot be considered useful at this time .
Premenopausal patients with one or more
positive nodes but without evidence of metastatic disease elsewhere should be considered
candidates for adjuvant therapy. However, the
question of whether adjuvant cytotoxic chemotherapy, immunotherapy, or hormonal therapy
should be given and for how long remains in the
investigative stage. Adjuvant chemotherapy
with CMF cannot be considered of proven value
for the general population of patients, and every
effort should be made to include these patients
in clinical trials to establish the value of adjuvant
therapy.
The choice of therapy for the patient with
extensive disease also has become more complex. ER+ patients of advanced age with cutaneous, pleural , nodal, early bone, or nodular
pulmonary disease may respond well to estrogen administration , and on re-exacerbation ,
androgen or prednisone. Approximately 25% of
these patients will show regression of the tumor
when estrogen is stopped-the "rebound "
phenomenon, which has also been described
after androgen and tamoxifen therapy.
The premenopausal , ER+ patient currently is treated with oophorectomy initially and ,
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TABLE 11
Metastatic Disease
Postmenopausal

Premenopausal
ER+

ER-

ER-

Oophorectomy
Medical adrenalectomy
Surgical adrenalectomy
Antiestrogen
Chemotherapy

Chemotherapy

upon relapse, adrenalectomy or hypophysectomy . In a series studied at the Medical College
\ of Virginia, 16 medical adrenalectomy with amino. glutethimide and dexamethasone is almost as
effective as surgical adrenalectomy and does
not preclude a response to surgical adrenalectomy when tumor again progresses. A schematic flow sheet to indicate serial treatment
measures for advanced disease is shown in
Table 11.
The presence of extensive long bone metastases or vertebral destruction should be handled with radiotherapy to as small an area as
possible. Some cases may require prophylatic
internal fixation of the femur or humerus.
Prompt laminectomy and decompression of the
spinal cord in epidural tumors or vertebral collapse is always worthwhile . Chemotherapy
rather than hormonal therapy will almost always
be required in such cases because of ttie need
for rapid control of the disease to ensure continued ambulation.
CNS involvement can frequently be handled with moderate doses of radiation to the
whole brain (3000 rads in 1 0 fractions), but
meningeal involvement may also require intrathecal Methotrexate administration.
Liver metastases, extensive visceral in-

ER+
Estrogen
Estrogen rebound
Androgen
Androgen rebound
Antiestrogen
Progesterone or Corticosteroid
Chemotherapy

volvement, bone marrow, or interstitial pulmonary involvement present almost insurmountable management problems. However,
some patients with liver metastases and marked
liver dysfunction respond to cytotoxic drugs and
these should be instituted . When the situation is
desperate , doxorubicin containing regimens
with their higher initial response rate are the current choice. Extensive involvement of more than
one organ requires cytotoxic drugs for systemic
effect and radiation of painful or obstructing
masses of tumor.
Corticosteroids provide some short-term
palliation of the patient with interstitial pulmonary involvement. When bone marrow involvement with persistent low blood counts precludes full doses of multiple drugs administered
on the usual time schedules, reduction of doses
and/or the number of drugs may still provide
some means of control .
Some general tenets of management of
the patient with breast cancer are summarized
in Table 12 . In all cases the most critical aspect
of management is the close support of the patient by an understanding and sympathetic physician.

REFERENCE$
TABLE 12
Tenets of Breast Cancer Management
1 . Make long-term plans for the management of the patient
at the onset.
2. Preserve or restore mobility and CNS function.
3. Treatment of painful lesions is virtually always of benefit.
4. Start treatment for local recurrences or systemic disease
early; do not delay.
5. Neither despair nor hold out unrealistic promise of cure.
Hope is warranted by the facts .
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